drugset / Trial / NCT03793478
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Phase 1/2
Active not recruiting
65 enrolled
Daiichi Sankyo
Children's Oncology Group · collabInnovative Therapies For Children with Cancer Consortium · collab
NaSequentialOpen-labelTreatment
Summary
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.
Timeline
- Start
- 2018-08-15
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quizartinib | Small molecule | — | Oral |
| Background | Cytarabine | Small molecule | 75 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 500 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 2000 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Background | Hydrocortisone | Other / unclassified | — | — |
| Background | Methotrexate | Small molecule | — | — |
| Background | Prednisolone | Other / unclassified | — | — |